Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,188Revenue (TTM) $M66.1Net Margin (%)10.1Altman Z-Score54.2
Enterprise Value $M763EPS (TTM) $0.1Operating Margin %-6.9Piotroski F-Score7
P/E(ttm)145Beneish M-Score77.7Pre-tax Margin (%)10.1Higher ROA y-yY
Price/Book2.810-y EBITDA Growth Rate %-34.7Quick Ratio33.4Cash flow > EarningsY
Price/Sales17.65-y EBITDA Growth Rate %-32.7Current Ratio33.4Lower Leverage y-yY
Price/Free Cash Flow483y-y EBITDA Growth Rate %--ROA % (ttm)1.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)1.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M137ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ACHNJoel Greenblatt 2016-06-30 Reduce-0.03%$7.48 - $9.86
($8.57)
$ 8.691%Reduce -65.39%191,792
ACHNJoel Greenblatt 2016-03-31 Buy 0.05%$5.63 - $10.79
($7.36)
$ 8.6918%New holding554,125
ACHNFirst Eagle Investment 2014-03-31 Sold Out -0.0054%$3.08 - $4.2
($3.51)
$ 8.69148%Sold Out0
ACHNFirst Eagle Investment 2013-12-31 Buy 0.01%$2.43 - $3.46
($2.9)
$ 8.69200%New holding600,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
($7.34)
$ 8.6918%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
($9.57)
$ 8.69-9%Reduce -50.00%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
($6.15)
$ 8.6941%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
($6.37)
$ 8.6936%New holding22,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Apelian DavidChief Medical Officer 2015-12-30Sell10,000$10.5-17.24view
Fenton Mary KayCFO 2015-12-28Sell43,500$10.08-13.79view
VITULLO NICOLEDirector 2015-11-11Sell550,000$10.17-14.55view
VITULLO NICOLEDirector 2015-09-25Sell9,310$8.225.72view
VITULLO NICOLEDirector 2015-08-14Sell37,843$7.5115.71view
Fenton Mary KayEVP and CFO 2015-01-23Sell13,125$16-45.69view
Deshpande MilindPresident and CEO 2015-01-21Sell100,000$15-42.07view
RA CAPITAL MANAGEMENT, LLC 2014-09-30Sell1,332,014$10.2-14.8view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-26Sell2,372,915$11.17-22.2view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-23Sell2,595,071$11.29-23.03view

Quarterly/Annual Reports about ACHN:

News about ACHN:

Articles On GuruFocus.com
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 

More From Other Websites
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen's Phase 2 Trial... Sep 23 2016
11:51 am Achillion Pharma's Odalasvir shows potential to shorten the treatment duration to as little... Sep 23 2016
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial... Sep 23 2016
Coverage initiated on Achillion Pharma by Wedbush Sep 23 2016
Biotech Movers: Lantheus Holdings Inc (LNTH) and Achillion Pharmaceuticals, Inc. (ACHN) Sep 13 2016
Achillion, J&J's HCV Combo Drug Positive in Phase IIa Trial Sep 12 2016
Achillion Announces 100% SVR Reported in Janssen's Phase 2a Trial Evaluating Triple Combination of... Sep 09 2016
Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of... Sep 09 2016
Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement... Sep 06 2016
8 Major FDA Decisions and Trial Results to Watch for in September Sep 02 2016
Achillion to Present at Two Upcoming Investor Conferences Sep 01 2016
Achillion to Present at Two Upcoming Investor Conferences Sep 01 2016
ETF’s with exposure to Achillion Pharmaceuticals, Inc. : August 30, 2016 Aug 30 2016
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US :... Aug 29 2016
Gilead Sciences: Still Dominating Hepatitis C But… Aug 17 2016
ACHILLION PHARMACEUTICALS INC Financials Aug 12 2016
Is Achillion Pharmaceuticals (ACHN) Stock a Solid Choice Right Now? Aug 12 2016
Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored... Aug 11 2016
ETF’s with exposure to Achillion Pharmaceuticals, Inc. : August 9, 2016 Aug 09 2016
Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference Aug 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)